Trioxane Dimers Having Surprisingly High Anticancer Activities and Surprisingly Long-lasting Antimalarial Activities

Artemisinin (1), a monomeric 1, 2, 4 trioxane, is usually administered for the treatment of multi-drug resistant malaria. However, studies have determined that artemisinin not only possesses excellent anti-malarial properties but also considerable anti-cancer activities. Dimeric trioxanes also possess potent anti-cancer activities and can inhibit the growth of prostate cancer C2H cells almost as effectively as Gemcitabine, a clinically used anticancer agent. Recently, scientists at JHU designed, synthesized and evaluated a series of novel hydrolytically stable trioxane dimers that also exhibit highly potent anticancer activities and long lasting anti-malarial effects. Description (Set) Proposed Use (Set) The artemisinin-derived trioxane dimers described in this invention may be used alone, or in combination therapy regimes, for the treatment of cervical cancer and potentially, other varieties of mucosal and epidermal tumors. The novel compounds demonstrate a greater potency and selectivity towards cervical cancer cells than previous trioxane monomers and dimers, which may suggest a lower therapeutic index requirement for clinical use and fewer toxic effects to normal cell populations. These compounds will also be useful for the treatment of malarial infections.

Inventor(s): Posner, Gary H.

Type of Offer: Licensing



« More Medical Patents

---